CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 122 enrolled
Drug / intervention
Lamotriginedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00516139
NCT00516139Phase 3Completed
CompareCT.gov

Lamotrigine Extended-Release in Elderly Patients With Epilepsy

GlaxoSmithKline·interventional·Posted Aug 15, 2007·Updated Jan 18, 2017

In Brief

A Phase 3 clinical trial evaluating Lamotrigine for Epilepsy. Completed, enrolled 122 participants across 63 sites.

Detailed Summary

This study is being conducted to determine the safety and tolerability of lamotrigine (LTG) in elderly patients with epilepsy. This study will be carried out using an extended-release formulation of lamotrigine (LTG-XR) that will allow once-a-day dosing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 15, 2007
Enrollment StartAug 1, 2007
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 18.9 years ago

Interventions

Lamotriginedrug

Open-label